Appointment of Dr. Mauricio Futran (DIN: 11699767), as an Additional Director of the Company, categorized as Non-Executive Non-Independent Director
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The Board of Directors approved the appointment of Dr. Mauricio Futran as an Additional Director (Non-Executive Non-Independent) effective May 12, 2026, based on the recommendation of the Nomination and Remuneration Committee. The appointment is subject to shareholder approval at the ensuing 42nd AGM scheduled for August 4, 2026. The announcement was part of a broader Board meeting that also approved audited financial results for FY26 showing standalone profit after tax of Rs. 36,310.50 lakhs (up from Rs. 25,942.54 lakhs in FY25), recommended a final dividend of Rs. 34 per equity share, and approved a capacity expansion of 120.5 KL at Unit 1 with an investment of Rs. 143.4 crores.
This is a routine board composition update with no immediate shareholder implications. The appointment adds industry expertise to the board and requires only standard shareholder ratification. The strong financial results and dividend recommendation are positive signals for investors.